School of Medicine
Showing 1-10 of 19 Results
Ronald W. Davis
Professor of Biochemistry and of Genetics
Current Research and Scholarly InterestsWe are using Saccharomyces cerevisiae and Human to conduct whole genome analysis projects. The yeast genome sequence has approximately 6,000 genes. We have made a set of haploid and diploid strains (21,000) containing a complete deletion of each gene. In order to facilitate whole genome analysis each deletion is molecularly tagged with a unique 20-mer DNA sequence. This sequence acts as a molecular bar code and makes it easy to identify the presence of each deletion.
Professor of Pediatrics (Hematology/Oncology) at the Lucile Salter Packard Children's Hospital
Current Research and Scholarly InterestsHematology/Oncology, Phase I drug studies for childhood cancer, overcoming multidrug resistance in leukemia and solid tumors, biology and treatment of acute nonlymphocytic leukemia, early detection of central nervous system leukemia by measuring growth, factor binding proteins.
The J.G. Jackson and C.J. Wood Professor in Chemistry
BioProfessor Dai’s research spans chemistry, physics, and materials and biomedical sciences, leading to materials with properties useful in electronics, energy storage and biomedicine. Recent developments include near-infrared-II fluorescence imaging, ultra-sensitive diagnostic assays, a fast-charging aluminum battery and inexpensive electrocatalysts that split water into oxygen and hydrogen fuels.
Born in 1966 in Shaoyang, China, Hongjie Dai began his formal studies in physics at Tsinghua U. in Beijing (B.S. 1989) and applied sciences at Columbia U. (M.S. 1991). His doctoral work under Dr. Charles Lieber at Harvard U. (Ph.D. 1994) focused on charge-density waves and superconductivity. During postdoctoral research at Rice U. with Dr. Richard Smalley, he developed carbon nanotube probes for atomic force microscopy. He joined the Stanford faculty in 1997, and in 2007 was named Jackson–Wood Professor of Chemistry. Among many awards, he has been recognized with the ACS Pure Chemistry Award, APS McGroddy Prize for New Materials, Julius Springer Prize for Applied Physics and Materials Research Society Mid-Career Award. He has been elected to the American Academy of Arts and Sciences, AAAS and National Academy of Sciences.
The Dai Laboratory has advanced the synthesis and basic understanding of carbon nanomaterials and applications in nanoelectronics, nanomedicine, energy storage and electrocatalysis.
The Dai Lab pioneered some of the now-widespread uses of chemical vapor deposition for carbon nanotube (CNT) growth, including vertically aligned nanotubes and patterned growth of single-walled CNTs on wafer substrates, facilitating fundamental studies of their intrinsic properties. The group developed the synthesis of graphene nanoribbons, and of nanocrystals and nanoparticles on CNTs and graphene with controlled degrees of oxidation, producing a class of strongly coupled hybrid materials with advanced properties for electrochemistry, electrocatalysis and photocatalysis. The lab’s synthesis of a novel plasmonic gold film has enhanced near-infrared fluorescence up to 100-fold, enabling ultra-sensitive assays of disease biomarkers.
Nanoscale Physics and Electronics
High quality nanotubes from his group’s synthesis are widely used to investigate the electrical, mechanical, optical, electro-mechanical and thermal properties of quasi-one-dimensional systems. Lab members have studied ballistic electron transport in nanotubes and demonstrated nanotube-based nanosensors, Pd ohmic contacts and ballistic field effect transistors with integrated high-kappa dielectrics.
Nanomedicine and NIR-II Imaging
Advancing biological research with CNTs and nano-graphene, group members have developed π–π stacking non-covalent functionalization chemistry, molecular cellular delivery (drugs, proteins and siRNA), in vivo anti-cancer drug delivery and in vivo photothermal ablation of cancer. Using nanotubes as novel contrast agents, lab collaborations have developed in vitro and in vivo Raman, photoacoustic and fluorescence imaging. Lab members have exploited the physics of reduced light scattering in the near-infrared-II (1000-1700nm) window and pioneered NIR-II fluorescence imaging to increase tissue penetration depth in vivo. Video-rate NIR-II imaging can measure blood flow in single vessels in real time. The lab has developed novel NIR-II fluorescence agents, including CNTs, quantum dots, conjugated polymers and small organic dyes with promise for clinical translation.
Electrocatalysis and Batteries
The Dai group’s nanocarbon–inorganic particle hybrid materials have opened new directions in energy research. Advances include electrocatalysts for oxygen reduction and water splitting catalysts including NiFe layered-double-hydroxide for oxygen evolution. Recently, the group also demonstrated an aluminum ion battery with graphite cathodes and ionic liquid electrolytes, a substantial breakthrough in battery science.
Professor of Radiology (General Radiology) and, by courtesy, of Pediatrics (Hematology/Oncology)
Current Research and Scholarly InterestsAs a physician-scientist involved in the care of patients and investigating novel pediatric molecular imaging technologies, my goal is to develop innovative, safe, accurate and efficient imaging solutions to significant problems in disease diagnosis. My research team works on novel cellular imaging techniques for improved detection and characterization of malignant tumors in pediatric patients, for the diagnosis of immune system disorders and for in vivo evaluation of stem cell transplants.
Edward J. Damrose, MD, FACS
Associate Professor of Otolaryngology - Head and Neck Surgery (Laryngology) at the Stanford University Medical Center
Current Research and Scholarly InterestsAdvanced MRI imaging for laryngeal cancer and swallowing disorders; applications of robotics in microlaryngeal surgery; high speed digital imaging of vocal fold vibration; the effects of hormones and anabolic steroids on vocal function.
Professor of Radiology (General Radiology) and, by courtesy, of Bioengineering
Current Research and Scholarly Interests1. MRI of Breast Cancer, particularly new techniques. Currently being explored are techniques including ultra high spatial resolution MRI and contrast-agent-free detection of breast tumors.
2. MRI-guided interventions, especially MRI-compatible remote manipulation and haptics
3. Medical Mixed Reality. Currently being explored are methods of fusing patients and their images to potentially improve breast conserving surgery, and other conditions.
Mark M. Davis
The Burt and Marion Avery Family Professor
Current Research and Scholarly InterestsMolecular mechanisms of lymphocyte recognition and differentiation; Systems immunology and human immunology; vaccination and infection.
Adam de la Zerda
Assistant Professor of Structural Biology and, by courtesy, of Electrical Engineering
Current Research and Scholarly InterestsMolecular imaging technologies for studying cancer biology in vivo
Professor of Radiology (Canary Cancer Center) and, by courtesy, of Electrical Engineering
BioDr. Demirci is currently a Professor at Stanford University School of Medicine with tenure at the Canary Center for Early Cancer Detection. Prior to his Stanford appointment, he was an Associate Professor of Medicine at Brigham and Women's Hospital, Harvard Medical School and at Harvard-MIT Division of Health Sciences and Technology serving at the Division of Biomedical Engineering, Division of Infectious Diseases and Renal Division. He leads a group of 20+ researchers focusing on micro- and nano-scale technologies. He received his B.S. degree in Electrical Engineering in 1999 as a James B. Angell Scholar (summa cum laude) from University of Michigan, Ann Arbor. He received his M.S. degree in 2001 in Electrical Engineering, M.S. degree in Management Science and Engineering in 2005, and Ph.D. in Electrical Engineering in 2005, all from Stanford University.
The Demirci Bio-Acoustic MEMS in Medicine Lab (BAMM) specializes in applying micro- and nanoscale technologies to problems in medicine at the interface between micro/nanoscale engineering and medicine. Our goal is apply innovative technologies to clinical problems. Our major research theme focuses on creating new microfluidic technology platforms targeting broad applications in medicine. In this interdisciplinary space at the convergence of engineering, biology and materials science, we create novel technologies for disposable point-of-care (POC) diagnostics and monitoring of infectious diseases, cancer and controlling cellular microenvironment in nanoliter droplets for biopreservation and microscale tissue engineering applications. These applications are unified around our expertise to test the limits of cell manipulation by establishing microfluidic platforms to provide solutions to real world problems at the clinic.
Our lab creates technologies to manipulate cells in nanoliter volumes to enable solutions for real world problems in medicine including applications in infectious disease diagnostics and monitoring for global health, cancer early detection, cell encapsulation in nanoliter droplets for cryobiology, and bottom-up tissue engineering. Dr. Demirci has published over 120 peer reviewed publications in journals including PNAS, Nature Communications, Advanced Materials, Small, Trends in Biotechnology, Chemical Society Reviews and Lab-chip, over 150 conference abstracts and proceedings, 10+ book chapters, and an edited book. His work was highlighted in Wired Magazine, Nature Photonics, Nature Medicine, MIT Technology Review, Reuters Health News, Science Daily, AIP News, BioTechniques, and Biophotonics. He is fellow-elect of the American Institute of Biological and Medical Engineering (AIMBE, 2017). His scientific work has been recognized by numerous national and international awards including the NSF Faculty Early Career Development (CAREER) Award (2012), the IEEE-EMBS Early Career Achievement Award (2012), Scientist of the year award from Stanford radiology Department (2017). He was selected as one of the world’s top 35 young innovators under the age of 35 (TR-35) by the MIT Technology Review at the age of 28. In 2004, he led a team that won the Stanford University Entrepreneur’s Challenge Competition and Global Start-up Competition in Singapore. His work has been translated to start-up companies including DxNow, KOEK Biotechnology and LEVITAS. There has been over 10,000 live births in the US, Europe and Turkey using the sperm selection technology that came out of Dr. Demirci's lab. He has been cited over 2500 times within the last two years (H index, 48).
Professor (Research) of Medicine (BMIR), of Biomedical Data Science and, by courtesy, of Health Research and Policy
Current Research and Scholarly InterestsDr. Desai is the Director of the Quantitative Sciences Unit. She is interested in the application of biostatistical methods to all areas of medicine including oncology, nephrology, and endocrinology. She works on methods for the analysis of epidemiologic studies, clinical trials, and studies with missing observations.